This development further expands the company’s Finished Dosage Form (FDF) portfolio and reflects its focus on reliable, responsible, and sustainable partnership models across the pharmaceutical value chain. WELDING PHARMA FDF supports partners with value-oriented solutions ranging from development and market access support to long term supply concepts.
“With this milestone, we continue to strengthen our role as a reliable partner for the pharmaceutical industry,” said Lars Hallmayer, Managing Director, WELDING GmbH & Co. KG. “Our approach combines regulatory expertise, transparent collaboration, and a long-term commitment to responsible business practices.”
The company views this authorization as part of its broader strategy to create sustainable economic value through trusted partnerships and international market expertise. With decades of experience in the pharmaceutical sector and a strong global network, WELDING PHARMA FDF works closely with partners to develop and implement tailored product and licensing solutions.
Further steps toward market availability will be taken in accordance with applicable national requirements.
For media inquiries, please contact:
https://welding.eu/…
WELDING GmbH & Co. KG, headquartered in Hamburg, is a family-owned company with over 70 years of international experience. The company specializes in the procurement and distribution of pharmaceutical active ingredients, food additives, and feed additives, as well as the development, approval, licensing, and delivery of generic pharmaceuticals. In this regard, WELDING also offers a comprehensive range of services in the field of quality assurance and regulatory affairs.
WELDING GmbH & Co. KG
Esplanade 39
20354 Hamburg
Telefon: +49 (40) 35908-0
Telefax: +49 (40) 35908-251
http://www.welding.de
Head of Marketing & Communications
Telefon: +494035908197
E-Mail: presse@welding.eu
